EBS Stock Analysis: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$7.55
-0.46 (-5.81%)
▼
5d:
-8.99%
30d:
-10.07%
90d:
-8.43%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called EBS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EBS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: EBS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.56
Based on -0.1% avg growth
INTRINSIC VALUE TODAY
$7.80
3.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $7.54, which is considered slightly low relative to its 30-day fair value range of $7.98 to $8.39. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.8) compared to its historical average (13.9). Remarkably, the market is currently pricing in an annual earnings decline of 14.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EBS is in a downtrend. The price is currently testing key support at $7.93. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: EBS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+49.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EBS is in a downtrend. The price is currently testing key support at $7.93. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: EBS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+49.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.98 -
$8.39
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
Holding EBS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.8%)
- BULLISH: Trading 49.8% below Wall St target ($12.00)
- CAUTION: 5-day price weakness (-9.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$7.98 -
$8.39
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.93
Resistance Level
$8.63
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.80
Wall Street Target
$12.00
(+49.8%)
Revenue Growth (YoY)
-29.7%
Earnings Growth (YoY)
-93.8%
Profit Margin
-1.3%
Valuation Discount vs History
-14.1% cheaper
PE vs Historical
8.8 vs 13.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.1%
(market-implied from PE analysis)
1-Year Target
$7.21
(-10%)
2-Year Target
$6.49
(-19%)
3-Year Target
$5.84
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→14)
$9.22
(+15%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -4.2%)
$17.42
(+118%)
Base:
(SPY PE: 8.8, Growth: -4.2%)
$7.04
(-12%)
Bear:
(PE: 7.5, Growth: -4.2%)
$5.98
(-25%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.8 to 13.9
Stabilization Target:
$12.65
(+57.9%)
PE Expansion Potential:
+57.9%
Share & Embed Analysis
Last updated: July 14, 2026 11:13 AM ET
Data refreshes hourly during market hours. Next update: 12:13 PM
Data refreshes hourly during market hours. Next update: 12:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
